BIOR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIOR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biora Therapeutics's Revenue per Share for the three months ended in Sep. 2024 was $0.01.
During the past 12 months, Biora Therapeutics's average Revenue per Share Growth Rate was 1085.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -87.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -89.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Biora Therapeutics was -78.80% per year. The lowest was -88.70% per year. And the median was -87.30% per year.
For the Biotechnology subindustry, Biora Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biora Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Biora Therapeutics's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Biora Therapeutics (OTCPK:BIOR) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Biora Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Athyrium Opportunities Iii Co-invest 1 Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Surbhi Sarna | director | ONE PENUMBRA PLACE, ALAMEDA CA 94502 |
Aditya P. Mohanty | director, officer: Chief Executive Officer | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Jill Ann Howe | director | C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Athyrium Capital Management, Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Opportunities Fund (a) Lp | 10 percent owner | 605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158 |
Hutan Hashemi | officer: Chief Compliance Officer | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Damon Silvestry | officer: Chief Operating Officer | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Jeffrey D. Alter | director | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Athyrium Opportunities Iii Acquisition Lp | 10 percent owner | 505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017 |
Harry Stylli | director, officer: Chairman & CEO | 3595 JOHN HOPKINS CT, SAN DIEGO CA 92121 |
Matthew T Cooper | officer: Chief Scientific Officer | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Athyrium Opportunities Advisers Llc | 10 percent owner | 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104 |
Athyrium Opportunities Associates Gp Llc | 10 percent owner | 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104 |
Athyrium Opportunities Associates Lp | 10 percent owner | 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104 |
From GuruFocus
By Marketwired • 11-14-2024
By Marketwired • 05-06-2024
By Marketwired • 04-30-2024
By Marketwired • 10-29-2024
By GuruFocus Research • 08-13-2024
By Marketwired • 11-07-2024
By GuruFocus News • 11-13-2024
By Marketwired • 08-08-2024
By Marketwired • 05-20-2024
By Marketwired • 12-30-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.